Management of hepatitis C in the setting of liver transplantation

Abstract

Each year, 5000 to 6000 liver transplantations are performed in the United States, 40% of which are for hepatitis C-related end-stage liver disease. Infection of liver allograft is universal and is associated with an accelerated rate of disease progression. Unfortunately, antiviral therapy after transplantation is less effective and often is beset with complications. This article reviews antiviral therapies and the factors that may influence the response in patients who have HCV infection both immediately before and after liver transplantation.